Distinguishing SARS-CoV-2 bonafide re-infection from pre-existing minor variant reactivation.

导出 OA

翻译打印收藏纠错

第一作者： Juliana D,Siqueira

第一单位： Programa de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil.

作者： Juliana D,Siqueira ^[1] ; Livia R,Goes ^[2] ; Brunna M,Alves ^[1] ; Ana Carla P,da Silva ^[3] ; Pedro S,de Carvalho ^[1] ; Claudia,Cicala ^[4] ; James,Arthos ^[4] ; João P B,Viola ^[5] ; Marcelo A,Soares ^[6]

作者单位： Programa de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. ^[1] Programa de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. ^[2] Hospital do Câncer II, Instituto Nacional de Câncer, Avenida Via Binário do Porto, 831, Rio de Janeiro, RJ 20081-250, Brazil. ^[3] Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. ^[4] Programa de Imunologia e Biologia de Tumores, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. ^[5] Programa de Oncovirologia, Instituto Nacional de Câncer, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Departamento de Genética, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro, RJ 21941-402, Brazil. Electronic address: masoares@inca.gov.br. ^[6]

关键词 Intrahost variation Multiple infection Re-infection Reactivation SARS-CoV-2